EuropaBio calls for specific guidance on labelling of biosimilars

September 22, 2014 7:10 AM

Last week, EuropaBio has published a statement giving the perspective of the healthcare biotechnology industry on the labelling of biosimilars.

Members of the EuropaBio Healthcare Council call on the European Medicines Agency (EMA) to define specific guidance on the labelling of biosimilars, in order to take into account the specificities of these products and facilitate their understanding and acceptance by patients and physicians.  In particular, EuropaBio supports a transparent label that combines information on both the biosimilar and the reference product.

“We believe biosimilars need to be labelled in a clear and transparent way in order to facilitate the understanding and acceptance of these products on the part of physicians and patients” explained Nathalie Moll, EuropaBio Secretary General. “Transparent labelling allows physicians to make informed decisions when selecting the most appropriate medicinal product for their patients, and we welcome any initiatives by European regulators to provide more specific guidance on this aspect”.

Format and content of labelling is governed by the EMA’s Quality Review of Documents guidance (EMA/627621/2011) which does not distinguish between biosimilars, generics and hybrid products. Because of the nature of biosimilars, which are recognised as a distinct category of medicinal products and have a different regulatory approval pathway than both originator products and generics in the EU, EuropaBio suggests the labelling of biosimilars should combine information on both the biosimilar and the reference product, so that it is clear whether the data presented was generated for the reference or the biosimilar product, and which indications have been approved for each product.

EuropaBio Statement on Labelling of Biosimilars

Source: EuropaBio

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!